Oil prices hold sharp losses with focus on secondary India tariffs
On Tuesday, Stifel analysts maintained their positive stance on Trevi Therapeutics (NASDAQ:TRVI), reiterating a Buy rating and a $15 price target for the company’s stock. This aligns with the broader analyst consensus, as InvestingPro data shows analyst targets ranging from $11 to $29, with five analysts recently revising their earnings expectations upward. The endorsement comes as Trevi Therapeutics shared additional information from its RIVER RCC trial and gathered insights from specialists at an event organized in conjunction with the American Thoracic Society (ATS).
The event, which took place ahead of the Phase 2b CORAL trial results, allowed Trevi Therapeutics to present more detailed findings from their study. The company, which maintains a strong financial health score according to InvestingPro analysis and holds more cash than debt on its balance sheet, highlighted the consistency of treatment effects, patient-reported outcomes such as cough severity and quality of life measures, and the timing of adverse events, which were mostly observed in the first week, regardless of the dosage.
Specialists expressed significant optimism about the efficacy of Trevi’s Haduvio™, particularly noting its centrally-acting mechanism of action (MoA), which is different from peripheral approaches and agnostic to the ion channel responsible for cough. This distinction has led to unprecedented positive data, according to the specialists, who have reportedly never seen such results before.
While there is some uncertainty regarding the placebo effect in the upcoming Phase 2b CORAL data, physicians praised Trevi for its high-quality study design, which has taken into account lessons from past study failures. The company’s approach has been commended for its potential to deliver reliable and meaningful results in the treatment of RCC and IPF/ILD-related chronic cough. For deeper insights into Trevi’s financial health, growth prospects, and detailed analyst coverage, access the comprehensive Pro Research Report available exclusively on InvestingPro, which covers over 1,400 US stocks with expert analysis and actionable intelligence.
In other recent news, Trevi Therapeutics reported a smaller-than-expected loss per share for Q1 2025, with an EPS of -$0.09, surpassing analyst forecasts of -$0.13. This indicates improved operational efficiency or cost management. Trevi also announced additional analyses from its Phase 2a RIVER trial, which evaluated Haduvio for refractory chronic cough (RCC). The trial results showed a significant reduction in cough frequency, with Haduvio achieving a 67% reduction from baseline and a 57% reduction on a placebo-adjusted basis. Further analyses highlighted improvements in patient-reported outcomes, reinforcing the potential of Haduvio as a treatment for RCC. Additionally, Raymond (NSE:RYMD) James maintained a Strong Buy rating on Trevi Therapeutics, setting a price target of $29, reflecting confidence in Haduvio’s efficacy and potential expanded use. The company is also progressing with its Phase 2b CORAL trial for IPF chronic cough patients, anticipating top-line data this quarter. These developments indicate a positive trajectory for Trevi’s ongoing clinical programs.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.